AMAG Pharmaceuticals Inc.'s Makena (hydroxyprogesterone caproate injection) failed to achieve both co-primary endpoints in the PROLONG confirmatory study required by the US FDA when it granted the product accelerated approval in 2011, but that doesn't necessarily mean the pre-term birth drug will need to be withdrawn.
While PROLONG was meant to confirm FDA's accelerated approval decision for Makena, it's unclear whether the agency will require AMAG...







